Literature DB >> 15940779

Leflunomide induced acute interstitial pneumonia.

Michio Takeishi1, Yuji Akiyama, Haruhiko Akiba, Daisuke Adachi, Motoharu Hirano, Toshihide Mimura.   

Abstract

We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide. We diagnosed interstitial pneumonia, probably induced by leflunomide because acute respiratory failure was preceded by elevated serum liver enzyme concentration and hypertension. She showed dramatic improvement with prednisolone and cholestyramine. Prompt treatment may improve the prognosis. In Japan, leflunomide has been implicated as a possible cause to initiate or exacerbate interstitial pneumonia in patients with RA according to postmarketing surveillance. Clinicians should exclude pulmonary disease prior to initiating leflunomide treatment in patients with RA on the basis of a thorough history and physical examination, and chest radiograph.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940779

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Leflunomide in combination therapy for rheumatoid arthritis.

Authors:  Ruth L Savage
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  Suppressed wound healing in a patient with rheumatoid arthritis taking leflunomide (arava).

Authors:  D Miller Wise
Journal:  Perm J       Date:  2011

3.  Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.

Authors:  Kanako Inaba; Takahide Arimoto; Mari Hoya; Kei Kawana; Shunsuke Nakagawa; Shiro Kozuma; Yuji Taketani
Journal:  Med Oncol       Date:  2011-03-10       Impact factor: 3.064

Review 4.  Leflunomide: friend or foe for systemic lupus erythematosus?

Authors:  Guo-Cui Wu; Xiao-Di Xu; Qiong Huang; Hua Wu
Journal:  Rheumatol Int       Date:  2012-09-08       Impact factor: 2.631

Review 5.  Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.

Authors:  Nicola Alcorn; Sarah Saunders; Rajan Madhok
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.

Authors:  Ildiko Fanny Horvath; Antonia Szanto; Zoltan Csiki; Peter Szodoray; Margit Zeher
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

7.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 8.  Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.

Authors:  Li-Ta Keng; Mong-Wei Lin; Hsien-Neng Huang; Kuei-Pin Chung
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.